Electrospun Rapamycin-Eluting Polyurethane Fibers for Vascular Grafts
- 688 Downloads
To develop rapamycin-eluting electrospun polyurethane (PU) vascular grafts that could effectively suppress local smooth muscle cell (SMC) proliferation.
Rapamycin (RM) was incorporated in PU fibers by blend electrospinning using three distinct blending methods. The drug release profiles and the bioavailability of RM-containing PU fibers in the form of fibrous mats and vascular grafts were evaluated up to 77 days in vitro.
RM-contained PU fibers generated by the three distinct blending methods exhibited significantly different fiber diameters (200–500 nm) and distinct RM release kinetics. Young’s moduli of the electrospun fibrous mats increased with higher RM contents and decreased with larger fiber diameters. For all blending methods, RM release kinetics was characteristic of a Fickian diffusion for at least 77 days in vitro. RM-PU fibers generated via powder blending showed the highest encapsulation efficiency. The RM in grafts made of these fibers remained bioactive and was still able to inhibit smooth muscle cell proliferation after 77 days of continual in vitro release.
Electrospun RM-containing PU fibers can serve as effective drug carriers for the local suppression of SMC proliferation and could be used as RM-eluting scaffolds for vascular grafts.
KEY WORDSdrug release electrospinning rapamycin restenosis smooth muscle cell
bovine serum albumin
Dulbecco’s Modified of Eagle’s Medium
fetal bovine serum
1, 1, 3, 3, 3-Hexafluoro-2-Propanol
high performance liquid chromatography
normal saline-isopropyl alcohol solution
phosphate buffered saline
percutaneous transluminal coronary angioplasty
smooth muscle cell
tissue culture polystyrene
ACKNOWLEDGEMENTS AND DISCLOSURES
Jingjia Han and Shady Farah equally contributed to this paper. This work was supported by a translational research grant by HUB (DU/BIOMED-IDR/HUJI) from Drexel University and The Hebrew University of Jerusalem. We thank Dr. Gozde Senel-Ayaz (Drexel BIOMED) for her assistance with SEM and Dr. Wahid Khan (IDR) for his assistance with developing the analytical method used to assess drug release.
- 4.Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998–1008.Google Scholar
- 5.Kim YH, Park SW, Lee SW, Park DW, Yun SC, Lee CW, et al. Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. Circulation. 2006;114:2148–53.Google Scholar
- 12.Montero RB, Vial X, Nguyen DT, Farhand S, Reardon M, Pham SM, et al. bFGF-containing electrospun gelatin scaffolds with controlled nano-architectural features for directed angiogenesis. Acta Biomater. 2012;8:1778–91.Google Scholar
- 20.Uttayarat P, Perets A, Li M, Pimton P, Stachelek SJ, Alferiev I, et al. Micropatterning of three-dimensional electrospun polyurethane vascular grafts. Acta Biomater. 2010;6:4229–37.Google Scholar
- 24.Okner R, Oron M, Tal N, Nyska A, Kumar N, Mandler D, et al. Electrocoating of stainless steel coronary stents for extended release of paclitaxel. J Biomed Mater Res A. 2009;88:427–36.Google Scholar
- 26.Mack MJ, Banning AP, Serruys PW, Morice MC, Taeymans Y, Van Nooten G, et al. Bypass versus drug-eluting stents at three years in SYNTAX patients with diabetes mellitus or metabolic syndrome. Ann Thorac Surg. 2011;92:2140–6.Google Scholar
- 27.Barner HB. Status of percutaneous coronary intervention and coronary artery bypass. Eur J Cardio-Thorac. 2006;30:419–24.Google Scholar
- 35.Ferron GM, Jusko WJ. Species differences in sirolimus stability in humans, rabbits, and rats. Drug Metab Dispos. 1998;26:83–4.Google Scholar
- 37.Verreck G, Chun I, Rosenblatt J, Peeters J, Dijck AV, Mensch J, et al. Incorporation of drugs in an amorphous state into electrospun nanofibers composed of a water-insoluble, nonbiodegradable polymer. J Control Release. 2003;92:349–60.Google Scholar
- 40.Innocente F, Mandracchia D, Pektok E, Nottelet B, Tille JC, de Valence S, et al. Paclitaxel-eluting biodegradable synthetic vascular prostheses: a step toward reduction of neointima formation? Circulation. 2009;120(11 Suppl):S37–45.Google Scholar